Bioseparations and Downstream Processing
Mixture of three amino acids as stabilizers replacing albumin in lyophilization of new third generation recombinant factor VIII GreenGene F
Article first published online: 23 OCT 2012
DOI: 10.1002/btpr.1640
Copyright © 2012 American Institute of Chemical Engineers (AIChE)
Additional Information
How to Cite
Paik, S. H., Kim, Y. J., Han, S. K., Kim, J. M., Huh, J. W. and Park, Y. I. (2012), Mixture of three amino acids as stabilizers replacing albumin in lyophilization of new third generation recombinant factor VIII GreenGene F. Biotechnol Progress, 28: 1517–1525. doi: 10.1002/btpr.1640
Publication History
- Issue published online: 4 DEC 2012
- Article first published online: 23 OCT 2012
- Accepted manuscript online: 26 SEP 2012 05:52AM EST
- Manuscript Revised: 31 AUG 2012
- Manuscript Received: 5 MAY 2012
Funded by
- Green Cross Corporation
- Abstract
- Article
- References
- Cited By
Keywords:
- albumin;
- factor VIII;
- lyophilization;
- formulation;
- protein stabilization
Abstract
A formulation with stabilizers replacing albumin was developed for lyophilization of recombinant factor VIII (FVIII), GreenGene F (WHO INN: beroctocog alfa), to achieve stability and eliminate safety issues of blood-derived albumin. L-Arginine (hydrophilic amino acid, positively charged side chain), L-glutamic acid (hydrophilic amino acid, negatively charged side chain), and L-isoleucine (hydrophobic amino acid, nonpolar) were selected as stabilizers, and the mixture of the three amino acids were optimized. The mixture had results comparative with albumin and other commonly used stabilizers showing good preservation of recombinant FVIII during lyophilization, robust stability with consistently high recovery of FVIIII, very low aggregate formation, and good storage stability without alterations in protein characteristics. In vivo test results showed that the efficacy was maintained and had no signs of toxicity. The study demonstrated that the three amino acid mixture acts as a good stabilizer for lyophilization of recombinant FVIII and as a safe excipient. © 2012 American Institute of Chemical Engineers Biotechnol. Prog., 2012

1520-6033/asset/BTPR_left.gif?v=1&s=a5be2ff5a0fe6ccdaad74a6d128c142e5f71a8da)
1520-6033/asset/BTPR_right.gif?v=1&s=992d113a3e61fc9d3571812359165df86cf830e4)
